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Intensity Modulated Proton Therapy
Treatment robustnessa b s t r a c t
Background and purpose: Intensity-modulated proton therapy (IMPT) is expected to result in clinical ben-
efits by lowering radiation dose to organs-at-risk (OARs). However, there are concerns about plan robust-
ness due to motion. To address this uncertainty we evaluated the robustness of IMPT compared to the
widely clinically used volumetric modulated arc therapy (VMAT) on weekly repeated computed tomogra-
phies (CT).
Materials and methods: 19 patients with oesophageal cancer were evaluated. IMPT and VMAT plans were
created on a planning 4-Dimensional CT (p4DCT) and evaluated on weekly repeated 4DCTs (r4DCT). In
case of inadequate target coverage or unacceptable high dose to normal tissue, re-planning was per-
formed. Dose distributions of the r4DCTs were warped to p4DCT, resulting in an estimated actual given
dose (EAGD).
Results: Compared to VMAT, IMPT resulted in significantly lowered dose to heart, lungs, spleen, liver and
kidneys. For IMPT, target coverage was adequate (after max 1 replanning) in 17/19 cases. In two cases
target coverage remained insufficient. However, in one of these patients the summed dose was insuffi-
cient (due to tumor shrinkage) while weekly coverage was adequate. For the other patient the target cov-
erage was also insufficient by VMAT, due to large anatomical changes during treatment. For VMAT,
adequate target coverage was achieved in 18/19 cases without re-planning. However, for reasons of high
OAR dose re-planning was required in two cases.
Conclusion: IMPT reduces the dose to OARs significantly, while achieving adequate target coverage in the
majority of patients. Re-planning was necessary for both IMPT and VMAT due to anatomical changes.
 2020 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 151 (2020) 66–72 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Radiotherapy plays a pivotal role in the curative treatment of
oesophageal cancer patients [1]. However, thoracic radiotherapy
is accompanied by serious risks of complications caused by dose
to organs-at-risk (OARs), particularly to the heart and lungs [2–
5]. Despite the development of new photon-based technologies,
such as intensity modulated radiotherapy (IMRT) and volumetric
modulated arc therapy (VMAT), radiation dose to normal tissues
is still substantial [6].
Proton therapy (PT) reduces the normal tissue dose compared
to the current standard photon therapy, due to its steep dose gra-
dient. Several proton planning studies have shown the possibility
to decrease the dose to OARs, such as heart, lungs and bone mar-
row, as compared to photon techniques [7–13]. The use of passive
scattering proton therapy (PSPT) resulted in a decrease in postop-
erative complications compared to 3D conformal radiotherapy(3D-CRT) and IMRT [14]. Moreover, in the setting of definitive
chemoradiotherapy, a survival benefit was seen after two and five
years [15]. Intensity modulated proton therapy (IMPT), using pen-
cil beam scanning (PBS) delivery, decreases the dose to OARs even
further, compared to PSPT [16].
However, clinical implementation of IMPT for thoracic indica-
tions faces several challenges [17,18]. This modality is more sensi-
tive to density changes in the beam path, potentially increasing the
risks of over and under dosing. Density changes can occur during
treatment due to cardiac action, breathing motion, changes in gas-
tric filling or other general anatomical changes. Furthermore, the
movement of the target and OARs caused by breathing, could inter-
fere with the time structure of dose delivery, potentially resulting
in dose inhomogeneities (interplay effects). This is especially true
for distal oesophageal cancers that move markedly in craniocaudal
direction due to breathing motion [19].
The OAR dose sparing capabilities of IMPT in the treatment of
oesophageal cancer are promising, while clinical implementation
R.M. Anakotta et al. / Radiotherapy and Oncology 151 (2020) 66–72 67is impeded by uncertainties caused by anatomical changes and
breathing motion. Therefore, our aim was to evaluate the robust-
ness of IMPT for distal oesophageal cancer, in terms of target cov-
erage and normal tissue dose, during the full length of the




Twenty consecutive patients with histologically proven oeso-
phageal cancer were included for this in silico planning study.
These patients, over 18 years of age and with anWHO performance
score of 0–2, were scheduled for neo-adjuvant (nCRT) or definitive
(chemo)radiotherapy (d(C)RT). All patients were staged according
to the TNM 7 [20]. This study was approved by the Medical Ethical
Committee and all patients provided written informed consent
(clinicaltrial.gov NCT03024138).Imaging and image registration
Prior to their treatment, all patients underwent a planning 4DCT
scan (p4DCT) with oral contrast, followed by weekly repeat 4DCT
scans (r4DCT) without contrast agents, during treatment. The scans
were performed on a 64-slice CT scanner (Somatom AS Open 64-RT
Pro, Siemens Medical Systems, Erlangen, Germany), with 2-mm
slice thickness and an in-plane resolution of 1.0 mm. Patients were
positioned using an arm rest. An Anzai belt (Anzai Medical, Tokyo,
Japan) was used to monitor the respiratory motion. The CT images
were reconstructed into 10 respiratory phase bins and an average
CT (av_p4DCT, av_r4DCT). The av_p4DCT was registered to each
av_r4DCT by rigid registration focused on bony anatomy (similar
to CBCT-based repositioning) and a deformable image registration
(DIR) was performed, using the ANACONDA algorithm [21], in the
RayStation treatment planning system (TPS) (v4.99, RaySearch
Laboratories, Stockholm, Sweden).Delineation
The gross tumor volume of the primary tumor (GTVp) and
pathological lymph nodes (GTVn), were delineated by a radiation
oncologist on the av_p4DCT, using all diagnostic information (CT,
positron emission tomography (PET) CT, endoscopy, endoscopic
ultrasound). The GTVp was expanded to a clinical target volume
(CTVp), to encompass the mediastinal fatty tissue surrounding
the tumor volume for over 3 cm craniocaudally, following the
oesophageal or gastric mucosa. For creation of the CTVn, the GTVn
was expanded 7 mm, excluding anatomical borders [22]. Next, an
internal target volume (ITV) was created to encompass the CTV
in all respiratory phases of the 4DCT. Finally, a planning target vol-
ume (PTV) was generated using a uniform expansion of the ITV of
8 mm to account for setup uncertainties. The following OARs were
delineated: lungs, heart, spinal cord, liver, spleen and kidneys.
Thereafter, all the target volumes were warped from the av_p4DCT
to the av_r4DCTs, using DIR. The warped GTVs, CTVs and ITVs were
evaluated and manually adjusted if necessary. Original copies of all
warped structures were preserved for subsequent analysis. OARs
were delineated on all av_r4DCTs for weekly dose evaluations. To
evaluate the quality of the warped target volumes (ITV1) compared
to the manually adjusted target volumes (ITV2), we calculated the





For each patient, the clinically prescribed dose was used for
treatment planning for both VMAT and IMPT plans. In our patient
cohort three different dose prescriptions were used: 41.4 Gy (23
fractions of 1.8 Gy, nCRT), 50.4 Gy (28 fractions of 1.8 Gy, dCRT),
or 51 Gy (17 fractions of 3 Gy, dRT). All treatment plans were made
by two experienced radiation therapists (RTTs) on the av_p4DCTs,
using the RayStation TPS. The oral contrast (HU >120) was overrid-
den with 1.000 g/cm3. The VMAT plans were created with Col-
lapsed Cone, using two ipsilateral arcs. All VMAT plans were
optimized, ensuring at least 95% of the prescribed dose coverage
at 98% of the PTV. The following dose constraints (EQD2) were used
for OARs: for the spinal cord, the maximum dose was D0.1 cm3
50 Gy, mean lung dose (MLD) 20 Gy, lung V5 70%, lung V20
30%, mean heart dose (MHD) 26 Gy, mean liver dose 20 Gy,
mean spleen dose (MSD) 20 Gy, mean kidney dose 18 Gy. Hot-
spots of 107% of the prescribed dose were limited to 2 cm3. For
the IMPT plans, often three beam directions were chosen (one
anterior, two posterior-oblique). During optimisation, auto-spot
spacing was used to distribute the spots. The treatment machine
had a spot size (in air at isocenter) of 3 mm (r) at 230 MeV and
a minimum energy of 70 MeV. Furthermore, a pencil beam dose
algorithm was used for dose calculation. IMPT plans were robustly
optimized on the ITV using the following settings: 8 mm for setup
and 3% for range uncertainties [23,24]. All dose parameters are
reported in Gy, assuming a relative biological effectiveness (RBE)
of 1.1 for protons.
Robustness of all IMPT plans was evaluated by simulating 52
error scenarios (26 for VMAT), using 8 mm for setup uncertainties,
and 3% for proton range uncertainties. Setup uncertainties were
simulated by shifting the planning isocenter isotropically in 26
directions, with each 8 mm shift from the center to the surface
of a sphere. The plans were accepted if the ITV D98 was >95% of
the prescribed dose in the voxel-wise minimum dose distribution
[25], and all normal tissue dose constraints were met in the nom-
inal plan. For VMAT no robustness evaluation was performed on
the final treatment plan.Plan perturbations and evaluation
The VMAT and IMPT plans created on the av_p4DCT were re-
calculated on the weekly av_r4DCTs, simulating 26 error scenarios
for photons or 52 for protons (2 mm for both setup uncertainties,
and for IMPT 3% range uncertainties). The 2-mm setup uncertainty
has been established from an internal assessment, accounting for
imaging vs. treatment isocenter accuracy, as well as intra-
fractional setup errors. The voxel-wise minimum dose distribution
was used to evaluate ITV D98 on each av_r4DCT, the voxel-wise
maximum dose distribution was used to evaluate the spinal cord
D0.1 cm3, while the nominal plan dose was used to evaluate the
other normal tissue constraints on each av_r4DCT. If the manually
adjusted ITV D98 on an av_r4DCT was <94%, or the spinal cord
D0.1 cm3 was >51 Gy, normal tissue D0.1 cm3 was >115% of pre-
scribed dose, or the OAR thresholds were not met, re-planning
was performed on that av_r4DCT. The adjusted plan was then re-
calculated on the remaining weekly av_r4DCTs, and evaluated as
described above. For each patient, the total dose distribution deliv-
ered over the course of treatment was accumulated on the
av_p4DCT. The computed dose per voxel for each av_r4DCT was
warped to the av_p4DCT, accumulated and then evaluated. Dose
was accumulated accounting 3–5 fractions per av_r4DCT, depend-
ing on the prescribed dose. This resulted in an estimated actual
given dose (EAGD). After re-planning, the accumulation included
the previously given fractions until plan adaption.
68 Robustness of proton therapy in oesophageal cancerStatistics
Paired samples T-test was used to conclude whether differences
in group means were statistically significant (p  0.05).
Results
One of the 20 included patients withdraw the informed consent
after one week of treatment and was excluded from further analy-
sis. All remaining patients had mid- or distal oesophageal cancer.
Patient characteristics are listed in Table 1.
Adequate target coverage was achieved in all patients for both
VMAT and IMPT at baseline, with a mean coverage of 99% of the
prescribed dose for the ITV D98. For one VMAT plan (no. 16), it
was not possible to keep all dose constraints for OARs (lung V5Table 1
Patient characteristics.
Characteristic n (19) (%)
Gender Female 4 21.1
Male 15 78.9
Age Median (range) 68 (56–84)
Tumor location Mid-distal 1 5.3
Distal 18 94.7






Treatment 41.4 Gy in 23 fx * 15 78.9
50.4 Gy in 28 fx * 3 15.8
51 Gy in 17 fx 1 5.3
GTV volume (cc) mean (SD) 78 (±51)
CTV volume (cc) mean (SD) 280 (±134)
ITV volume (cc) mean (SD) 315 (±143)
No. of r4DCTs 4 3 15.8
5 14 73.7
6 2 10.5
Abbreviations: fx: fractions, GTV: gross tumor volume, SD: standard deviation, ITV:
internal target volume, r4DCT: repeated 4-dimensional computed tomography.
* Combined with weekly carboplatinum/paclitaxel.
Table 2
Dose to organs-at-risk (nominal baseline plan, without replanning).





VMAT IMPT VMAT IMPT VMAT IMPT VMAT
1 0–180 0/160/200 38.60 31.81 19.80 6.17 96
2 0–180 0/160/200 35.84 31.37 13.76 5.70 58
3 0–180 0/145/215 25.35 28.77 19.78 9.64 98
4 0–180 0/145/215 28.00 24.40 20.91 8.25 100
5 0–180 0/145/215 41.74 23.42 25.93 13.13 99
6 0–180 0/160/200 39.75 35.96 22.99 7.02 100
7 0–180 0/150/210 47.22 48.33 23.20 11.89 95
8 0–180 0/145/215 41.73 28.61 21.91 6.56 79
9 0–180 0/150/210 30.02 29.77 17.14 10.72 92
10 0–180 0/140/210 38.29 26.75 17.83 6.52 76
11 0–180 0/150/210 43.41 33.89 14.22 5.06 70
12 0–180 0/150/210 34.18 31.59 20.19 8.56 99
13 0–180 0/145/215 35.83 26.53 17.10 4.98 97
14 335–180 0/150/210 40.40 30.47 16.37 7.11 80
15 0–180 0/150/210 29.52 28.76 21.16 7.19 100
16 0–180 0/150/220 39.08 32.56 28.30 15.59 100
17 0–180 0/150/220 38.27 33.65 25.02 10.34 100
18 0–180 0/150/220 36.18 19.10 15.84 6.58 84
19 0–180 0/150/220 35.78 34.87 24.74 11.71 100
Mean 36.80 30.56 20.33 8.56 91
Mean difference 6.24 11.76 56.32
p-Value <0.001 <0.001 <0.001and V20, MHD) within the pre-defined boundaries due to the
extensive volume of the PTV. For IMPT, all dose constraints were
met and the MHD, MLD and MSD doses decreased with respect
to the VMAT plan by on average 11.8 Gy (range: 6.2–16.0),
5.0 Gy (range: 2.0–11.2) and 5.2 Gy (range: 0.7–10.5), respectively.
The heart V5 was decreased by 56% (range: 36–75) and the lung V5
by 33% (range: 8–60). The mean liver dose was decreased by
4.9 Gy, mean left kidney dose by 1.7 Gy and mean right kidney
dose by 1.5 Gy. These differences were all statistically significant
with a p-value of <0.01 (Table 2). Based on the NTCP model for
postoperative pulmonary complications by Thomas et al. [26],
the reduction in MLD would result in a risk reduction of postoper-
ative pulmonary complications by 11% (range: 2–30%, p = <0.01).
For all 19 patients, the average estimated actual given dose
(EAGD) ITV coverage without re-planning was 97% for VMAT and
93% for IMPT (range: 88–100% and 56–100%, respectively), result-
ing in adequate target coverage for 18 (95%) VMAT and 15 (79%)
IMPT cases (Supplementary A). After one re-planning, ITVs for 18
(95%) VMAT and 17 (89%) IMPT cases were adequately covered
(Fig. 1). Re-planning was required in five patients for VMAT accord-
ing to an av_r4DCT, of which three might have been unnecessary in
retrospect when considering the EAGD on the av_p4DCT (no. 4/8).
In two cases, the normal tissue dose was too high (no. 5/16), how-
ever, for one case re-planning could not lower the normal tissue
dose below threshold (no. 16). For this case, it remained impossible
to achieve adequate dose coverage after re-planning. For 3 out of
the 15 IMPT cases (no. 3, 5 and 15), re-planning was suggested
based on inadequate target coverage in a specific week. However,
in retrospect, when considering the final EAGD, this might have
been unnecessary. In two patients, inadequate dose distribution
was seen in the EAGD due to change in diaphragm position or pleu-
ral effusion, but adequate EAGD coverage was achieved after one
re-planning (no. 5/8). In two cases, no adequate EAGD coverage
could be achieved. In one case this was due to large changes in gas-
tric filling while using a ventral beam (no. 2). In the other case an
offset of diaphragm position resulted in reduced coverage (no. 16)
(Fig. 2).
The EAGD MHD and MLD was significantly different from initial
planned dose for both VMAT and IMPT. However, the EAGD Ddose5 (%) Lung mean
(Gy)
Lung V5 (%) Lung V20 (%) Spleen mean
(Gy)
IMPT VMAT IMPT VMAT IMPT VMAT IMPT VMAT IMPT
24 9.17 3.65 60 17 11 6 6.53 1.68
22 3.94 1.64 20 7 4 3 16.50 6.17
40 9.77 4.48 65 23 13 8 9.09 6.43
37 9.27 4.50 53 24 13 8 18.34 16.68
47 11.39 6.03 69 31 18 12 4.25 0.00
27 10.57 1.87 69 9 10 1 0.71 0.00
55 11.53 4.95 69 23 15 10 11.84 7.92
26 4.83 2.85 24 16 6 4 0.71 0.00
42 8.45 4.03 53 20 13 7 13.30 9.10
28 5.51 2.63 31 12 6 6 19.03 8.53
18 6.00 2.73 36 15 5 5 5.75 1.85
31 8.28 4.33 53 20 10 8 12.16 7.03
22 7.79 4.78 49 25 9 8 6.21 1.04
29 5.18 2.56 26 13 7 2 7.34 4.12
31 9.79 4.20 67 24 10 5 10.91 1.95
55 19.38 8.19 100 42 35 15 19.75 11.65
43 11.51 4.78 67 27 17 3 17.31 6.84
29 7.23 3.33 44 20 4 3 8.94 3.17
47 12.20 6.18 66 33 23 9 19.44 15.31
34 9.04 4.09 54 21 12 6 10.95 5.76
4.95 32.63 5.58 5.19
<0.001 <0.001 <0.001 <0.001
Fig. 1. Need for re-planning for VMAT and IMPT, based on estimated actual given dose.
Planning CT Repeat CT week 1 Repeat CT week 3 Repeat CT week 5
Fig. 2. Dose distributions of IMPT plans in coronal view for patient number 16. For the planning CT the nominal dose is shown with the original ITV (yellow). For the repeat
CTs (rCT) the voxelwise minimum is shown, the warped ITV (yellow), and the manually adjusted ITV (pink). The first row shows the original plan, the second row shows the
re-plan based on rCT1, the third row shows the re-plan based on rCT3.
R.M. Anakotta et al. / Radiotherapy and Oncology 151 (2020) 66–72 69MHD and MLD (between VMAT and IMPT) was not significantly
different from the baseline Ddose (Fig. 3).
The mean baseline ITV was 316 cc (range 116–572) (Supple-
mentary B). The CI between warped and adjusted structures was
on average 0.86 (range 0.72–0.99). The need for re-planning was
overestimated using the unadjusted warped ITVs on three rCTs
(one VMAT, two IMPT), the coverage was sufficient after manual
adjustment of the target. In contrast, there were three rCTs (oneVMAT, two IMPT) where the need for re-planning was underesti-
mated based on evaluation of the warped ITV, and re-planning
was required based on evaluation of the manually adjusted ITV.
However, this was considered only clinically relevant in one
patient. For the other two patients, the underdosage remained
restricted to air (dilated stomach), or the underdosage was
















Mean heart dose (Gy) Mean lung dose (Gy) 
Fig. 3. Mean heart dose (left) and mean lung dose (right) for all patients for the nominal plan, the estimated actual given dose (EAGD) and theDdose between VMAT and IMPT
for the nominal plan and in the EAGD. The EAGD includes re-planning.
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In this unique dataset of weekly repeated 4DCTs, we have
demonstrated that most IMPT plans (89%) for mid and distal oeso-
phageal cancer patients maintained their robustness throughout
the whole treatment course, however re-planning was needed
more often compared to VMAT.
In our dataset, re-planning was indicated in two (11%) VMAT
cases vs. four (22%) IMPT cases. Nyeng et al. previously showed
that re-planning was required in 31% (9/29) of IMRT plans as a con-
sequence of anatomical changes, based on one repeat CT [27]. In
their population, the largest differences in dose coverage were
caused by offsets in diaphragm position. More recently, Möller
et al. evaluated multiple proton SFUD plans on one repeat CT and
compared them to a standard IMRT plan [28]. In 6 of the 26
patients (23%), an offset in the diaphragm position was seen. The
robustly optimized SFUD plans were more robust to these changes
in diaphragm position than the IMRT plans. The authors explained
this because they used posterior beams in SFUD, which avoids
entrance through the diaphragm. These findings are in line with
the results of Yu et al., who proposed a method to select beam
angles that are least affected by diaphragmatic and respiratory
motion, which reduces the risk of dose errors [16].
In the current analysis, reasons for re-planning were hotspots
and inadequate target coverage, resulting from changes in dia-
phragm position, gastric filling or pleural effusion. The IMPT cases
in which no adequate coverage was achieved, contained a ventro-
lateral beam, which is more vulnerable to changes in gastric filling.
By choosing a beam setup without a ventrolateral beam, as per-
formed in additional analysis (Supplementary C), this problem
could be avoided.
Changes in gastric filling or pleural effusion can be detected by
daily CBCT, and the impact can be mitigated by using adaptive
radiotherapy. Offsets in diaphragm position can be more difficult
to detect, requiring 4D(CB)CT reconstructions [29]. Anticipating
planning strategies, such as the use of diaphragm or gastric filling
overrides, might be useful to reduce potential dose errors [30].
Breathing motion mitigation techniques, such as breath-hold or
mechanical ventilation, could reduce or regulate the breathing
motion for patients with large offsets in diaphragm position
[31,32]. For photon radiotherapy, robust optimisation and evalua-
tion of the VMAT treatment plans might improve their robustness
even further.To our knowledge, this is the first study describing the esti-
mated actual given dose (EAGD) evaluated using several weekly
repeated 4DCTs for oesophageal cancer patients. Accumulated
doses may provide insight in structural changes, whereas a single
repeat CTs will also reflect incidental changes in anatomy. The final
dose reduction to heart (average DMHD = 11.6 Gy) and lungs (av-
erageDMLD = 5.1 Gy) with the use of IMPT compared to VMAT was
substantial, despite the changes in EAGDMHD andMLD. Moreover,
the DMHD and DMLD did not change significantly over the course
of treatment. These consistent dose reductions seem clinically rel-
evant. Based on the model by Thomas et al. this MLD reduction
would result in a risk reduction of postoperative pulmonary com-
plications by 11% [26]. Retrospective series by the MD Anderson
group also found a significant reduction in postoperative wound
and pulmonary complications by use of PT [5]. More recently, the
results of their phase II randomized controlled trial were pub-
lished, which demonstrated that the dosimetric benefit of PT
resulted in a clinically significant reduction of complications after
neo-adjuvant chemoradiotherapy, especially in the postoperative
total toxicity burden [33].
In the current study we evaluated plans that were optimized
using a pencil beam dose calculation algorithm, which is widely
clinical common practice. The absence of 4D-optimisation and
Monte Carlo (MC) algorithms could be a limitation of this study.
Recent studies suggested that the use of MC calculations results
in a more realistic dose distribution [34]. However, it is unlikely
that these MC calculated plans would perform worse than the
current plans when evaluated on rCTs. According to Yu et al.,
4D-optimized IMPT plans could increase robustness and mitigate
the interplay effect of a single fraction [16], whereas Liu et al. per-
formed an interplay effect evaluation on IMPT plans for distal oeso-
phageal cancer, and found that the effects were small and clinically
acceptable [35].
No robust evaluation of the VMAT plans was performed at base-
line, as this was not clinical practice for photon treatment plans.
Incorporation of robustness evaluation for VMAT into clinical prac-
tice might improve the target coverage on the rCT’s for photon
treatments as well [36]. This will have to be evaluated in following
analysis.
Warping the delineations by DIR was adequate in most the
cases. Moreover, the differences between warped and adjusted tar-
get volumes were in the same range as described delineation
uncertainties between different observers [37,38]. However, a clin-
R.M. Anakotta et al. / Radiotherapy and Oncology 151 (2020) 66–72 71ical evaluation by a physician is essential to check for changes in
anatomy that could compromise the warped structure, such as
variations in diaphragm position or gastric filling.
In conclusion, IMPT resulted in comparable robustness of the
treatment plans in terms of target coverage, compared to VMAT.
A significant and consistent dose reduction to OARs could be
achieved over the course of treatment by use of IMPT.
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